HC Wainwright Lifts Earnings Estimates for Lyra Therapeutics

Lyra Therapeutics, Inc. (NASDAQ:LYRA) – Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for Lyra Therapeutics in a research report issued on Thursday, August 14th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($6.52) for the quarter, up from their prior estimate of ($8.87). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Lyra Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Lyra Therapeutics’ Q4 2025 earnings at ($7.14) EPS, FY2026 earnings at ($7.02) EPS, FY2027 earnings at ($6.35) EPS, FY2028 earnings at ($4.01) EPS and FY2029 earnings at ($1.33) EPS.

Separately, Wall Street Zen lowered Lyra Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 13th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Lyra Therapeutics currently has a consensus rating of “Hold” and an average target price of $100.00.

Lyra Therapeutics Trading Down 3.0%

Shares of LYRA opened at $7.09 on Monday. The stock has a 50 day moving average of $8.83 and a 200 day moving average of $8.36. Lyra Therapeutics has a 12 month low of $3.81 and a 12 month high of $37.50. The company has a market capitalization of $11.66 million, a price-to-earnings ratio of -0.24 and a beta of 0.16.

Lyra Therapeutics (NASDAQ:LYRA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($5.51) EPS for the quarter, beating analysts’ consensus estimates of ($5.79) by $0.28. The company had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.18 million. Lyra Therapeutics had a negative return on equity of 404.56% and a negative net margin of 5,043.64%.

Hedge Funds Weigh In On Lyra Therapeutics

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in shares of Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after acquiring an additional 7,190 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Lyra Therapeutics by 161.8% in the fourth quarter. JPMorgan Chase & Co. now owns 156,442 shares of the company’s stock worth $32,000 after acquiring an additional 96,681 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Lyra Therapeutics in the fourth quarter worth $51,000. Northern Trust Corp boosted its holdings in shares of Lyra Therapeutics by 56.2% in the fourth quarter. Northern Trust Corp now owns 286,310 shares of the company’s stock worth $59,000 after acquiring an additional 103,026 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Lyra Therapeutics by 15.3% in the fourth quarter. Geode Capital Management LLC now owns 885,966 shares of the company’s stock worth $183,000 after acquiring an additional 117,578 shares during the period. 95.62% of the stock is owned by institutional investors.

Lyra Therapeutics Company Profile

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.